Published online 2023 August 27.

Research Article

Immunoglobulin G Levels in Neonates After Receiving Phototherapy

Kayvan Mirnia ^{1,2}, Maryam Saeedi^{1,2}, Razieh Sangsari ^{1,2,*}, Fatemeh Mokhtarian Zavareh², Vahideh Mirnia³ and Nima Rezaei^{4,5,6}

¹Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran

²Children's Medical Center, Pediatric Center of Excellence, Tehran, Iran

³Faculty of Paramedicine, Babol University Medical Sciences, Babol, Iran

⁴Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

⁵Network of Immunity in Infection, Malignancy and Autoimmunity, Universal Scientific Education and Research Network, Tehran, Iran

⁶Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

corresponding author: Division of Neonatology, Children's Medical Center, Pediatric Center of Excellence, Tehran, Iran. Email: raz3532@yahoo.com

Received 2023 January 11; Revised 2023 June 30; Accepted 2023 July 25.

Abstract

Background: Most cases of newborn hyperbilirubinemia are physiologic; however, excessive unconjugated bilirubin is a potential neurotoxin. Phototherapy treats moderate to severe hyperbilirubinemia. If phototherapy increases immunoglobulin G (IgG) clearance, there is a chance of humoral immune disorders.

Objectives: The purpose of the study was to investigate the effect of phototherapy on the level of IgG in neonates.

Methods: This study investigated 40 full-term newborns with hyperbilirubinemia. Blood samples were taken before and 72 hours after phototherapy. The IgG level was measured by calorimetry tests.

Results: Phototherapy resulted in a decrease in IgG levels. The IgG level significantly decreased from 833.135 to 720.185 mg/dL. Before phototherapy, 12.5% of the population had low IgG levels; however, 32.5% had low IgG levels after the treatment.

Conclusions: According to the results of the study, intensive phototherapy caused a reduction in IgG levels. Since there was no significant decrease in IgG levels in neonates who received conventional phototherapy, it can be concluded that this treatment is safe in terms of IgG levels.

Keywords: Phototherapy, Newborns, Jaundice, Immune System

1. Background

Neonatal hyperbilirubinemia is a common issue in newborns, occurring in 60% of term neonates and 80% of preterm neonates; nevertheless, it is a transient phenomenon. Although most cases of hyperbilirubinemia are harmless, excessive unconjugated bilirubin can result in death (1). For more than 60 years, phototherapy has been employed to treat hyperbilirubinemia in newborns. Phototherapy's output spectrum and light intensity are impacted by the shape of the device and lamp. The effectiveness of phototherapy is influenced by the effective wavelength range (460 - 490 nm), light intensity, distance, and body surface area exposed to light (2).

Side effects of phototherapy include loose stools, macular erythematous rash, itchy rash with transient porphyrinuria, overheating, dehydration, hypothermia caused by undressing the newborn, bronze baby syndrome (in the presence of direct hyperbilirubinemia), paralytic ileus, and increasing prevalence of patent ductus arteriosus (PDA) in extremely preterm infants. Studies suggest that phototherapy can be linked with asthma, rhinitis, and conjunctivitis (3), in addition to thrombocytopenia (4) and cancer (5). Additionally, phototherapy can potentially alter the function of cell surface receptors, including growth factor receptors and lymphocyte subunits, and harm the deoxyribonucleic acid (DNA) and immune system of infants, along with impacting cytokines, such as tumor necrosis factor-alpha (TNF- α), interleukin (IL)-1 β , 6, and IL-8.

Furthermore, it can worsen immunoglobulin G (IgG) clearance and might lead to the development of humoral immune disorders. There are 5 different isotypes of Ig available: IgM, IgD, IgG, IgA, and IgE, each having a unique structure and function. The essential component for systemic immunity is IgG, which has the highest circulation and longest half-life. A wide variety of infections are prevented by IgG (6). Lower IgG levels

Copyright © 2023, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

might have no symptoms or might increase the risk of frequent infections, autoimmune diseases, allergies, malignancies, and infections, such as *Haemophilus influenza* and pneumococcus, that affect the airways. In patients with recurrent sinopulmonary infections, Picado et al. reported IgG subclass deficiencies in 8 - 57% of cases (7). There are very few studies conducted on the effect of phototherapy on IgG levels; as a result, no decisive conclusion can be made based on them. The absence of IgG measurement was noted in the studies.

2. Objectives

This study investigated the effects of phototherapy on IgG levels in term icteric newborns, as per the aforementioned materials.

3. Methods

3.1. Study Design and Patients

The present study was conducted at the Neonatal Ward of Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran, between March 1, 2021, and March 1, 2022. This study was a prospective investigation that aligned with the American Academy of Pediatrics (AAP) table on full-term newborns with indirect hyperbilirubinemia requiring conventional or intensive phototherapy (8). The phototherapy device was equipped with Tosan-manufactured LED lamps, from Iran, that emitted light with a wavelength of 400 - 500 nm. The lamps were discarded if they were used for more than 2000 hours. In conventional and intensive phototherapy, the distance between the newborn and the lamp was 50 and 15 - 20 cm, respectively. During the study, the neonates were put under phototherapy for at least 72 hours and were allowed to come out of it only for breastfeeding. Two blood samples were taken, one before and one at least 3 days after phototherapy.

Inclusion criteria: A gestational age exceeding 38 weeks, age range from day 1 to day 14 after birth, and meeting the AAP criteria (8) for phototherapy indication

Exclusion criteria: Direct hyperbilirubinemia, treatment with intravenous immunoglobulin (IVIG), packed cells and other blood products or/and exchange transfusion, a positive family history of immunodeficiency, congenital TORCH syndrome, congenital anomaly, albumin prescription, infectious and metabolic diseases, neonates whose parents did not consent to participate in the study, and receiving phototherapy for fewer than 3 days

3.2. Laboratory Tests

The analysis of the blood sample focused on IgG levels. Several items were analyzed, including complete blood count (CBC), bilirubin (total and direct), reticulocyte count, blood group of the newborn and mother, peripheral blood smear (PBS), and glucose-6-phosphate dehydrogenase (G6PD). To test for IgG serum level, 1 cc of venous blood was taken from the neonate and centrifuged at 3000 rpm for 10 minutes at room temperature. Additionally, the serum was separated and sent to the biochemistry department for calorimetry testing. The required amount of serum for testing was 10 landa. Anti-human IgG antibodies, when mixed with samples containing IgG, form insoluble complexes. These complexes cause an absorbance change, dependent upon the IgG concentration of the patient sample, that can be quantified by comparison from a calibrator of known IgG concentration. The implemented kit was AUDIT, Iran, and the IgG levels were read by the auto-analyzer Hitachi 917. It should be noted that for the measurement of this antibody, it was unnecessary to draw more blood from the newborn, and the same amount of blood that was delivered to the laboratory to check for bilirubin was enough to perform the level of this antibody.

3.3. Data Collection

Infants' characteristics, including gestational age, gender, date of birth, delivery method, weight, number of days of intensive or conventional phototherapy, bilirubin level, and mother's underlying diseases, were collected. Pre-prepared forms were used to record the data.

3.4. Sample Size

Considering the IgG mean comparing before and after phototherapy in participants and with an effect size of 0.05, margin of error of 0.05, and 85% study power, the sample size was estimated to be 40 participants.

3.5. Statistical Analysis

Mean and standard deviation were used to describe quantitative variables that had normal distribution, and median and interquartile range (IQR) were used for quantitative variables that had skewness. Quantitative variables are presented with frequency and percentage. For comparing the two groups, the Wilcoxon rank-sum test was used. The scatter plot was used to present the IgG levels before and after the phototherapy. Linear regression models were used to evaluate the factors affecting IgG drop in phototherapy. The multivariable linear regression model used all the variables from the univariate analysis with a stepwise approach. The significance levels for univariable and multivariable linear regression were 0.02 and 0.05, respectively. SPSS software (version 25) was used for the analysis of the data.

3.6. Ethics

Informed consent was obtained from the parents of the newborns, and no additional costs or blood sampling was imposed for IgG serum levels on the patients. The confidentiality of the data was maintained. At all stages of the research, the researchers were committed to the principles of the Declaration of Helsinki. The Ethics Committee of the Tehran University of Medical Sciences approved the present study (approval ID: IR.TUMS.CHMC.REC.1400.172).

4. Results

of full-term А total 40 newborns with hyperbilirubinemia were enrolled in the study. In this study, 19 neonates (47.5%) were male. The mean birth weight and age were 3332.13 ± 367.359 g and 6 ± 3 days, respectively. There were three and eight patients with Rh incompatibility and ABO incompatibility, respectively. Four patients were deficient in G6PD. In this study, reticulocyte count was within 0.4 - 7.5%, with an average of 1.9 \pm 2.33%. The normal level of reticulocytes based on the neonate's age on admission showed that 16 patients (40%) had high reticulocytes (9). The IgG level before phototherapy was within the range of 532.5 to 1543.6 mg/dL, with an average level of 833.135 mg/dL. The average IgG level after phototherapy was 720.185 mg/dL, ranging from 471.7 to 1640.3 mg/dL. The normal range of IgG level for healthy neonates based on age is 600-1670 mg/dL (4). Figure 1 shows IgG serum levels before and after phototherapy.

After phototherapy, the paired *t*-test revealed a significant decrease in the mean levels of IgG serum, hemoglobin, and bilirubin compared to before phototherapy (P = 0.000), as shown in Table 1. Spearman's correlation coefficient was utilized due to the non-normal distribution of newborns' weights. The results showed r = 0.11 and P-value = 0.47. No relationship was observed between weight and IgG levels before and after phototherapy. There was a higher decrease in IgG serum level after phototherapy for the group without Rh incompatibility compared to the incompatible group. However, this difference was not statistically significant (P = 0.25) according to the Mann-Whitney U test. The reduction in IgG serum level was higher in the non-ABO blood incompatible group after phototherapy; however, the difference was not significant (P = 0.07) based on the

Mann-Whitney U test. The statistical power of the test used was low due to the imbalance between the 2 groups; 8 patients had ABO blood incompatibility; nevertheless, 32 patients had no problems.

The non-parametric Kruskal-Wallis test revealed a lack of significant difference (P = 0.55) when investigating the correlation between the reduction of IgG serum levels after phototherapy and infant blood groups (Table 2). There was no correlation between age, gender, weight, and blood group with the decrease in IgG level. The regression test revealed a significant correlation between the decrease in IgG and intensive phototherapy (Table 3). The mean IgG was reduced by 0.25 mg/dL for every day of intensive phototherapy (Figure 2). No relationship was observed with conventional phototherapy (Table 3).

5. Discussion

The effect of phototherapy on IgG levels was analyzed in this study. Phototherapy led to a decrease in IgG levels after 3 days. According to the current study, there was a notable correlation between the reduction in IgG and intensive phototherapy. For every day of intensive phototherapy, the average IgG decreased by 0.25 mg/dL. The lack of a relationship in conventional phototherapy might be attributed to the small sample size. There was a smaller decrease in IgG levels in Rh-incompatible neonates than in the compatible groups. The small number of patients with Rh incompatibility (n=3), compared to those without problems (n = 37), led to an imbalance between the two groups, resulting in the low statistical power of the test used. A study can reveal a relationship by using an equal sample size. The ABO setup groups also show this pattern, and a larger sample size might reveal a clearer pattern in cases of lysis.

Although phototherapy is a safe method for the treatment of neonatal hyperbilirubinemia, it can result in complications, such as macular rash, hyperthermia, loose stools, and dehydration, which can lead to an increase in insensible water loss (3, 10). Studies on the harmful effects of phototherapy on DNA and immune and inflammatory systems are limited (11) and show inconsistent results. Phototherapy has been observed to impact the immune and inflammatory systems of newborns, according to studies. It was reported that the level of white blood cells (WBC) (12), IL-8, IL-1B (13), IL-2r (14), and TNF- α (10, 12) increased after phototherapy. Jahanshahifard et al.'s study (10) demonstrated that phototherapy can enhance the count of WBC and stimulate the release of TNF- α from the peripheral immune system (10, 15).

Studies suggest alterations in lymphocyte expression surface antigens. According to Elfeky et al.'s study,



Figure 1. Immunoglobulin G (IgG) serum levels before and after phototherapy

	Paired Samples Test	Paired Differences					
Pair		Mean± SD	95% Confidence Interval of the Difference		t	df	Sig. (Two-Tailed)
			Lower	Upper			
1	IgG1 - IgG2	110.4750 ± 202.4804	45.7186	175.2314	3.451	39	0.001
2	Hb1-Hb2	1.2725 ± 1.7118	0.7250	1.8200	4.701	39	0.000
3	Bili1 - Bili2	9.6025 ± 2.6252	8.7629	10.4421	23.134	39	0.000

Abbreviations: IgG, immunoglobulin G; Hb, hemoglobin; bili, bilirubin; SD, standard deviation.

Table 2. Correlation of Immunoglobulin G Serum Level Reduction with Blood Groups							
	n	Mean ± SD —	95% Confidence Interval for the Mean		— Minimum	Maximum	IgG Difference
			Lower Bound	Upper Bound	mininum	Maximum	igo bilerenee
A +	18	154.8556±221.77546	44.5692	265.1419	95.50	661.60	65.30
AB+	2	252.2500 ± 311.48054	2546.2916	3050.7916	32.00	472.50	252.25
B +	8	55.4375 ± 143.61573	64.6283	175.5033	96.70	338.40	13.65
0+	11	58.9818 ± 184.65689	65.0724	183.0360	377.70	410.60	97.30
Total	40	112.9500 ± 199.22072	49.2361	176.6639	410.60	661.60	

Abbreviations: IgG, immunoglobulin G; SD, standard deviation.

Models		Unstandardized Coefficients		Standardized Coefficients (Beta)	t	Sig.
		В	Standard Error	standardized coefficients (beta)	Ľ	515.
1						
	Constant	194.074	59.466		3.264	0.002
	Intensive phototherapy	-98.351	59.466	-0.259	-1.654	0.106
2						
	Constant	-113.219	145.227		-0.780	0.440
	Conventional phototherapy	73.949	46.872	0.248	1.578	0.123



Figure 2. Correlation of immunoglobulin G (Ig G) difference and intensive phototherapy

CD3+ and CD19+ lymphocyte percentages decreased in peripheral blood flow cytometry after 72 hours of phototherapy. The patients who had a decrease in CD3+ percentage visited the hospital more often in the 6-month follow-up (16). Kurt et al.'s study showed that phototherapy not only raised the levels of serum TNF- α , IL-1 β , and IL-8 but also reduced the percentage of CD3+ (13). Rashedy et al. (17), Eyada et al. (18), and Karabayir et al. (19) showed that phototherapy did not cause any variation in the percentage of lymphocytes in peripheral blood flow cytometry.

Phototherapy can impact both cellular and humoral immunity, causing a decrease in immunity levels through its effect on Igs. Phototherapy decreases Ig levels in newborns, according to Zheng et al. According to the aforementioned study, phototherapy results in an increase in the albumin-to-globin ratio due to globin destruction (6). The long lifespan of IgG is dependent on the neonatal Fc receptor (FcRn), a β 2 microglobulin that possesses two IgG binding sites. A possible mechanism for the reduction in IgG levels during phototherapy involves albumin binding to FcRn at a distinct site and increasing IgG degradation (20). Another possible mechanism is photodegradation. Sreedhara et al. demonstrated that protein damage can result from ambient light > 400 nm, typically over a 1-7 day period, due to small ultraviolet (UV) emissions (21).

The photodegradation of proteins, including antibodies, was introduced by Wei et al. (22). Antibodies catalyzed the reaction of singlet oxygen with water, resulting in the formation of hydrogen peroxide, known as the antibody-catalyzed water-oxidation pathway (ACWOP). This phenomenon was demonstrated by Wentworth et al.'s (23) group using different antibodies, which produced peroxide after light exposure. The authors suggest that antibodies employ water as an electron source, enabling the combination of singlet oxygen and water to produce H₂O₃ as the primary intermediate in a succession of reactions that ultimately culminate in the formation of H₂O₂. Additionally, the authors suggest that the conversion of singlet oxygen to hydrogen peroxide occurred as a result of the conserved tryptophan (Trp) in the antibodies' buried regions, not the surface-exposed areas (23-25).

The phosphorescence behavior of Trp residues is interesting due to their high flexibility and solvent accessibility (26). Tryptophan possesses solvated strong absorbance in the UV region (260 - 290 nm), making it a target of many photo-oxidation studies (27). Tryptophan is suggested as an endogenous photosensitizer increasing the oxygen-dependent photo-oxidation of tyrosine (28). When Trp is studied through photoexcitation, it leads to the creation of solvated electrons and Trp cation radicals. Solvated electrons reacting with molecular oxygen can result in the formation of superoxide anions. Tryptophan 53 is responsible for the increased efficiency of light energy transfer in monoclonal antibody 1 (mAb-1), and this finding might have a connection to ACWOP as a substrate generator. The pathway leads to site-specific Trp oxidation in mAb-1, which triggers different oxidative degradation mechanisms of other amino acids, including methionines, through photocatalysis (21).

However, the present study was limited by its small sample size and the imbalance between the 2 groups with and without ABO blood incompatibility. Therefore, the findings of this study should be interpreted with caution, and further research with larger sample sizes is needed to confirm these results.

5.1. Study Limitations

The study's limitations include a lack of long-term patient follow-up and investigation into growth patterns, infection rates, and hospitalization needs for reduced IgG serum levels after phototherapy. Decreasing IgG levels might be due to the reduction of maternal IgG by the age of the newborn, not phototherapy. Only a control group which do not receive phototherapy should answer this question. Therefore, another limitation of this study is the absence of a control group.

5.2. Conclusions

Phototherapy can increase the blood level of bilirubin; however, it might also reduce the body's immunity. According to the results of the study, intensive phototherapy caused a reduction in IgG levels. Since there was no significant decrease in IgG levels in neonates who received conventional phototherapy, it can be concluded that this treatment is safe in terms of IgG levels.

Acknowledgments

The authors would like to express their gratitude to the laboratory staff and other colleagues who cooperated with the study.

Footnotes

Authors' Contribution: M. K. participated in designing the evaluation and performed parts of statistical analyses. S. M. re-evaluated the clinical data, performed statistical analyses, and revised the manuscript. S. R. drafted the manuscript, interpreted the data, and revised the manuscript. M. V. conceived and designed the evaluation. M.F. collected the clinical data. R.N. re-analyzed the clinical and statistical data and revised the manuscript. All the authors read and approved the final manuscript.

Conflict of Interests: Funding or Research support: No; employment: No; personal financial interests: No; stocks or shares in companies: No; consultation fees: No; patents: No; personal or professional relations with organizations and individuals (e.g., parents and children, wife and husband, and family relationships): No; unpaid membership in a governmental or non-governmental organization: No; are you one of the editorial board members or a reviewer of this journal? Saeedi M., Sangsari R., and Mirnia K., are reviewers of this journal.

Data Reproducibility: The dataset presented in the study is available on request from the corresponding author.

Ethical Approval: The Ethics Committee of the Tehran University of Medical Sciences approved the present study (approval ID: IR.TUMS.CHMC.REC.1400.172).

Funding/Support: There was no funding/support.

Informed Consent: Informed consent was obtained from the parents of the newborns.

References

- Bhutani VK, Vilms RJ, Hamerman-Johnson L. Universal bilirubin screening for severe neonatal hyperbilirubinemia. *J Perinatol.* 2010;30 Suppl:S6–15. [PubMed ID: 20877410]. https://doi.org/10.1038/jp.2010.98.
- Itoh S, Okada H, Kuboi T, Kusaka T. Phototherapy for neonatal hyperbilirubinemia. *Pediatr Int.* 2017;59(9):959–66. [PubMed ID: 28563973]. https://doi.org/10.1111/ped.13332.
- Wang J, Guo G, Li A, Cai WQ, Wang X. Challenges of phototherapy for neonatal hyperbilirubinemia (Review). *Exp Ther Med.* 2021;21(3):231. [PubMed ID: 33613704]. [PubMed Central ID: PMC7859475]. https://doi.org/10.3892/etm.2021.9662.
- Khera S, Gupta R. Incidence of thrombocytopenia following phototherapy in hyperbilirubinemic neonates. *Med J Armed Forces India*. 2011;67(4):329–32. [PubMed ID: 27365841]. [PubMed Central ID: PMC4920634]. https://doi.org/10.1016/S0377-1237(11)60078-6.
- Kadivar M, Sangsari R, Saeedi M, Ghasemi Tehrani S. Association between Neonatal Phototherapy and Cancer during Childhood. *Iran J Neonatol.* 2020;11(3):104–8. https://doi.org/10.22038/ijn.2020.42623.1709.
- Zheng J, Wei C, Zhao M, Zhao D. Phototherapy is associated with the decrease in serum globulin levels in neonatal hyperbilirubinemia. *Biomed Rep.* 2019;10(1):63–9. https://doi.org/10.3892/br.2018.1166.
- Picado C, de Landazuri IO, Vlagea A, Bobolea I, Arismendi E, Amaro R, et al. Spectrum of Disease Manifestations in Patients with Selective Immunoglobulin E Deficiency. J Clin Med. 2021;10(18):4160. [PubMed ID: 34575269]. [PubMed Central ID: PMC8466644]. https://doi.org/10.3390/jcm10184160.
- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*. 2004;114(1):297-316. [PubMed ID: 15231951]. https://doi.org/10.1542/peds.114.1.297.
- 9. Yamada M, Chishiki M, Kanai Y, Goto A, Imamura T. Neonatal reticulocyte count during the early postnatal period.

Pediatr Neonatol. 2020;61(5):490-7. [PubMed ID: 32381419]. https://doi.org/10.1016/j.pedneo.2020.04.004.

- Jahanshahifard S, Ahmadpour-Kacho M, Pasha YZ. Effects of phototherapy on cytokines' levels and white blood cells in term neonate with hyperbilirubinemia. *J Clin Neonatol.* 2012;1(3):139–42. [PubMed ID: 24027710]. [PubMed Central ID: PMC3762030]. https://doi.org/10.4103/2249-4847.101696.
- Mesbah-Namin SA, Shahidi M, Nakhshab M. An Increased Genotoxic Risk in Lymphocytes from Phototherapy-Treated Hyperbilirubinemic Neonates. *Iran Biomed J.* 2017;21(3):182–9. [PubMed ID: 27869251]. [PubMed Central ID: PMC5392221]. https://doi.org/10.18869/acadpub.ibj.21.3.182.
- Mohamed SA, El-Askary A, Abd El-Tawab A, Khalifa MM. Effect of Neonatal Phototherapy on Serum Levels of Interleukin 1, 6, 8, TNFa and White Blood Cell Count. *Med J Cairo Univ.* 2018;86(7):3767-72. https://doi.org/10.21608/mjcu.2018.61491.
- Kurt A, Aygun AD, Kurt AN, Godekmerdan A, Akarsu S, Yilmaz E. Use of phototherapy for neonatal hyperbilirubinemia affects cytokine production and lymphocyte subsets. *Neonatology*. 2009;95(3):262–6. [PubMed ID: 19005263]. https://doi.org/10.1159/000171216.
- Abdel Wahab A, El Serafy T, Atef A, Eissa AN, Hussein MO. Effect of phototherapy on cytokines in neonatal jaundice. *Egypt J Neonatol.* 2005;6(1):7-12.
- Saber MA, Abd El Naby SA, Helwa MA, Deghedy RN. The influence of phototherapy for neonatal hyperbilirubinemia on tumour necrosis factor-α. *Menoufia Med J.* 2014;27(1):44–9. https://doi.org/10.4103/1110-2098.132735.
- Elfeky RAA, Abdel Fattah MA, Gaafar DM, Afifi HM. The effect of phototherapy on lymphocyte subsets in newborn infants. J Allergy Clin Immunol. 2012;129(2):AB12. https://doi.org/10.1016/j.jaci.2011.12.905.
- Rashedy FH, El-Hawy MA, Helwa MA, El-Shahat MI. Effect of Phototherapy on CD4, CD8 and Natural Killer Cells of Full Term Neonates with Indirect Hyperbilirubinemia. *Egypt J Immunol.* 2015;**22**(2):23–9. [PubMed ID: 28502141].
- Eyada IK, El Saie AL, Ibrahem GA, Riad NM. Effect of phototherapy on B and T lymphocytes in Egyptian infants suffering from neonatal jaundice. *Allergol Immunopathol (Madr)*. 2017;45(3):290–6. [PubMed ID: 27890454]. https://doi.org/10.1016/j.aller.2016.09.003.
- Karabayir N, Yilmaz S, Adal SE, Aydoğmuş Ç. The Effect of Phototherapy on the Lymphocyte Subsets in Newborn. *Turk Klin* J Med Sci. 2011;31(5):1245–9. https://doi.org/10.5336/medsci.2011-23229.
- Baldwin III WM, Valujskikh A, Fairchild RL. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. *Am J Transplant.* 2019;**19**(7):1881-7. [PubMed ID: 30903736]. [PubMed Central ID: PMC6591018]. https://doi.org/10.1111/ajt.15366.
- Sreedhara A, Yin J, Joyce M, Lau K, Wecksler AT, Deperalta G, et al. Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. *Eur J Pharm Biopharm*. 2016;**100**:38–46. [PubMed ID: 26707077]. https://doi.org/10.1016/j.ejpb.2015.12.003.
- 22. Wei Z, Feng J, Lin HY, Mullapudi S, Bishop E, Tous GI, et al. Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. *Anal Chem*. 2007;**79**(7):2797-805. [PubMed ID: 17319649]. https://doi.org/10.1021/ac062311j.
- Wentworth AD, Jones LH, Wentworth Jr P, Janda KD, Lerner RA. Antibodies have the intrinsic capacity to destroy antigens. *Proc Natl Acad Sci U S A*. 2000;97(20):10930–5. [PubMed ID: 11005865]. [PubMed Central ID: PMC27126]. https://doi.org/10.1073/pnas.97.20.10930.
- Nieva J, Kerwin L, Wentworth AD, Lerner RA, Wentworth Jr P. Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway. *Immunol Lett.* 2006;**103**(1):33-8. [PubMed ID: 16386801]. https://doi.org/10.1016/j.imlet.2005.11.020.

- Nieva J, Wentworth Jr P. The antibody-catalyzed water oxidation pathway-a new chemical arm to immune defense? *Trends Biochem Sci.* 2004;29(5):274–8. [PubMed ID: 15130564]. https://doi.org/10.1016/j.tibs.2004.03.009.
- Cioni P, Strambini GB. Acrylamide Quenching of Protein Phosphorescence as a Monitor of Structural Fluctuations in the Globular Fold. J Am Chem Soc. 1998;120(45):11749-57. https://doi.org/10.1021/ja9820543.
- Creed D. The Photophysics and Photochemistry of the near-Uv Absorbing Amino Acids-I. Tryptophan and Its Simple Derivatives. *Photochem Photobiol.* 1984;39(4):537-62. https://doi.org/10.1111/j.1751-1097.1984.tb03890.x.
- Babu V, Joshi PC. Tryptophan as an endogenous photosensitizer to elicit harmful effects of ultraviolet B. Indian J Biochem Biophys. 1992;29(3):296-8. [PubMed ID: 1324884].